CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

BIOLOGICAL5 trials

Sponsors

University of Washington

Conditions

Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8

Phase 1

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

Active, not recruitingNCT02157051

University of WashingtonHER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer +4

Start: 2015-06-01End: 2026-09-01Updated: 2026-02-17

Phase 2

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

Active, not recruitingNCT05242965

University of WashingtonLung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

Start: 2023-03-24End: 2026-12-31Updated: 2026-04-03

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Active, not recruitingNCT05455658

University of WashingtonAnatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8 +14

Start: 2022-11-17End: 2028-07-16Updated: 2025-10-24

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

RecruitingNCT07078604

University of WashingtonAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma

Start: 2026-04-11End: 2028-06-30Target: 20Updated: 2026-03-12

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

RecruitingNCT07112053

University of WashingtonAnatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma

Start: 2025-11-17End: 2028-12-31Target: 40Updated: 2026-03-09

Related Papers

546 A phase I dose escalation study of STEMVAC, a multi-antigen, multi-epitope Th1 selective plasmid-based vaccine, targeting stem cell associated proteins in patients with advanced breast cancer

Regular and Young Investigator Award Abstracts2022-11-0112 citations

1176 Optimizing immunization schedules for therapeutic vaccination

Regular and Young Investigator Award Abstracts2022-11-011 citations

Breast cancer stem cell autoantibodies to identify women with advanced breast cancer.

Journal of Clinical Oncology2018-05-201 citations

Vaccine targeting antigens associated with cancer stem cells/epithelial to mesenchymal transition inhibits triple negative breast cancer growth

The Journal of Immunology2018-05-011 citations